Home / Pharmaceutical / US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

Published: Jan 2011 | No Of Pages: 59 | Published By: Assessment Group

Product Synopsis

 
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 
 
Primary research on the oncology prescribing data that you are missing, directly from high-prescribing US oncologists regarding metastatice breast cancer: what they prescribe, when, and why. Case highlights include:
 
  • Triple negative metastatic breast cancer
  • Triple positive metastatic breast cancer
  • ER/PR positive HER2neu negative metastatic breast cancer
  • Metastatic breast cancer with multiple comorbidities
 
This report allows you to:
 
  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing & improving market strategies
  • Pinpoint needs of your target audience
  • Design messages to advance brand performance
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your competitor’s product fits
Executive Summary
 
Chapter 1: Introduction
Table 1. Treatment Options in Metastatic Breast Cancer
 
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
 
Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer
Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.1
Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.2
Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3
Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.4
Confidence managing patient with triple negative metastatic breast cancer
Figure 3.5
Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.6
Treatment of progressive triple negative metastatic breast cancer
Figure 3.7
Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.8
Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3. 9
Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.10
Changing therapy to manage neuropathy
Figure 3.11
Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.12
Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.13
Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.14
 
Chapter 4: Treatment of Patient with Triple Positive Metastatic Breast Cancer
Next step for patient with triple positive metastatic breast cancer
Figure 4. 1
Treatment of progressive disease, triple positive metastatic breast cancer
Figure 4.2
Single chemotherapy choices for progressive triple positive metastatic breast cancer
Figure 4.3
Combination chemotherapy, progressive triple positive metastatic breast cancer
Figure 4.4
Factors influencing treatment of progressive triple positive metastatic breast cancer
Figure 4.5
Treatment regimen for continued progression of triple positive metastatic breast cancer
Figure 4.6
Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer
Figure 4.7
Management of progressive disease, triple positive metastatic breast cancer
Figure 4.8
 
Chapter 5: Patient with ER/PR Positive HER2Neu Negative Metastatic Breast Cancer
Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.1
Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.2
Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.3
Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.4
Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.5
 
Chapter 6: Patient with Metastatic Breast Cancer with Multiple Comorbidities
Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 6.1
Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 6.2
Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 6.3
Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 6.4
Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities
Figure 6.5
 
Chapter 7: Summary
Appendix A: Survey Instrument
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +